News&Insight

For many people, hCG simply means the one or two lines on a pregnancy test. In fact, human chorionic gonadotropin (hCG) is both an important biomarker for the early detection of pregnancy and an analyte frequently used in professional healthcare to assess changes in early pregnancy, manage complex pregnancy-related situations, and monitor certain associated conditions. Understanding the value of hCG also means understanding its limits: a test detects a biological signal, while a complete assessment must also consider test timing, symptoms, medical history, and any necessary professional examinations.

Why hCG Is Central to Early Pregnancy Testing

hCG is a glycoprotein hormone composed of alpha and beta subunits. After embryo implantation, trophoblastic tissue associated with placental development begins to secrete hCG. The hormone then enters the maternal circulation, and a proportion is excreted into the urine through the kidneys. Its early physiological roles include supporting the corpus luteum and helping maintain the hormonal environment required for pregnancy. As pregnancy progresses, hCG concentrations typically rise rapidly during the early stages. [3,4]

From a testing perspective, hCG appears early, changes markedly in concentration during early pregnancy, and contains epitopes that can be recognized by specific antibodies. These properties make it suitable for both laboratory immunoassays and rapid tests based on formats such as immunochromatography and latex agglutination. [1–5]

hCG testing generally falls into two categories: qualitative and quantitative. Qualitative tests determine whether the hCG level in a sample meets the product's criteria for detection and usually report a positive or negative result. They are suitable for rapid screening and preliminary identification of pregnancy. Quantitative tests report a specific concentration and, when clinically appropriate, can be repeated at defined intervals to help assess changes over time.

hCG is not a single molecule with an unchanging structure. Intact hCG, hyperglycosylated hCG, the free beta subunit, and the urinary beta-core fragment are among the forms whose relative proportions vary with gestational stage and physiological status. [3–6] Mature pregnancy-test development therefore involves more than detecting low concentrations. It also requires systematic evaluation of antibody recognition, potential cross-reactivity, performance at high analyte concentrations, lot-to-lot consistency, stability, and conditions of actual use.

Urine POCT: An Established Option for Home and Primary-Care Testing Worldwide

Rapid urine hCG tests integrate immunological recognition, signal labeling, and chromatographic separation in a compact device, usually producing a visual result within minutes. Formats such as strips, cassettes, and midstream tests do not require large laboratory instruments, involve relatively few operating steps, and support user privacy. They have therefore been widely adopted in homes, pharmacies, primary-care facilities, and outpatient screening settings.

The World Health Organization's Model List of Essential In Vitro Diagnostics includes rapid urine hCG tests for non-laboratory settings as well as hCG immunoassays for clinical laboratories. [1] In many countries and regions, rapid urine hCG tests are also widely used for home self-testing. Guidance on reproductive-health POCT published by AACC—now the Association for Diagnostics & Laboratory Medicine (ADLM)—notes that pregnancy POCT can provide rapid information close to the user or patient and can be valuable when laboratory turnaround times do not meet an immediate clinical need. [2]

Home urine testing is non-invasive, convenient, rapid, and readily accessible. Behind this apparent simplicity is a carefully controlled immunochemical process: the sample migrates along a membrane, where labeled particles and immobilized antibodies work together to form a test signal. A separate control signal confirms sample migration and the basic operation of the test system. Reagent stability, membrane flow rate, sample volume, read time, and the clarity of the instructions can all affect reliability under actual conditions of use. [5]

Test timing remains critical. Ovulation and implantation do not occur on the same day in every cycle, and hCG may still be below a product's detection capability when testing is performed too early. Dilute urine or deviations from the test procedure can also affect the result. Real-world research shows that the earlier a test is taken before the expected menstrual period, the greater the likelihood of first obtaining a negative result in a pregnancy that is subsequently confirmed. [7] If a negative result is inconsistent with a delayed period or the user's physical condition, the product instructions should be followed. Anyone experiencing abdominal pain, vaginal bleeding, pronounced dizziness, or other warning symptoms should seek prompt medical evaluation rather than relying solely on a home pregnancy-test result.

Serum and Blood Testing: Additional Information for Professional and Specialized Settings

Blood-based hCG testing extends the value of this analyte from home screening into professional healthcare. Professional rapid tests can provide qualitative results, while serum immunoassays in central laboratories generally provide quantitative concentrations. Because hCG enters the maternal circulation before a proportion is excreted into urine, highly sensitive quantitative serum assays can usually detect lower hCG concentrations and enable serial quantitative monitoring when required. [2,4]

Quantitative serum hCG is commonly used in the assessment or monitoring of abdominal pain or bleeding during early pregnancy, suspected ectopic pregnancy, pregnancy of unknown location, possible early pregnancy loss, follow-up after assisted reproduction, and gestational trophoblastic disease. [2,4,12] Whole-blood POCT can provide rapid supporting information in emergency departments, outpatient clinics, preoperative assessments, and other professional settings where timely results are important.

In many professional settings, the pattern of change is more informative than a single measurement. Serum hCG typically rises rapidly in an early intrauterine pregnancy, but the rate of increase varies with the starting concentration and between individuals. Ectopic or nonviable pregnancies may show a slower rise, a plateau, or a decline, with overlap between different clinical situations. [4] A rise that appears normal therefore cannot, on its own, confirm an intrauterine location or embryonic viability. Likewise, an atypical pattern should not be interpreted independently of symptoms and ultrasound findings.

The limitations of urine testing deserve particular attention in higher-risk clinical settings. A large emergency-department study found that false-negative urine POCT results were uncommon overall but occurred more frequently among patients presenting with abdominal pain or vaginal bleeding, including some patients with ectopic pregnancy. [8] When a missed pregnancy or pregnancy complication could have serious consequences, serum testing and clinical follow-up are important.

Why a Positive hCG Result Does Not Always Mean Pregnancy

In routine early pregnancy testing among people of reproductive age, a positive hCG result primarily indicates the possibility of pregnancy. From a laboratory-medicine perspective, however, a positive result means that the test system detected hCG or produced an immunoreactive signal interpreted as hCG. That result alone does not establish the source of the signal.

Particular attention is required during perimenopause and after menopause. As ovarian hormonal feedback changes, the pituitary gland may produce small amounts of hCG, resulting in a persistent or relatively stable low-level elevation of serum hCG. This physiological phenomenon is recognized in authoritative literature and clinical guidance. If age, menstrual status, and other hormone results are overlooked, the finding may be mistaken for pregnancy or malignancy. [9,11]

Other possible causes include residual hCG following a recent delivery, miscarriage, or pregnancy termination; exogenous hCG used in assisted reproduction or obtained from another source; hCG-related molecules produced by gestational trophoblastic disease, germ-cell tumors, and certain other tumors; low-level hCG elevations that may be observed with impaired renal function; rare familial hCG syndrome; and immunoassay interference caused by heterophile antibodies or human anti-animal antibodies. [10–12]

Not every positive result unrelated to pregnancy is a technical “false positive.” hCG arising from the pituitary gland, a tumor, a recent pregnancy, or exogenous administration is genuinely present as an analyte. By contrast, factors such as heterophile antibodies may generate an immunoassay signal even when the corresponding circulating hCG is not present. Distinguishing among these sources can help avoid unnecessary anxiety, investigations, procedures, or treatment.

When a result is inconsistent with the clinical picture or remains persistently positive, healthcare professionals may investigate the cause using repeat testing, an alternative assay platform, comparison of urine and serum results, serial quantitative hCG measurements, related hormone tests, imaging, or other laboratory methods, as appropriate to the situation. [10,11] The central principle is clear: hCG is a highly valuable biomarker, but pregnancy status must still be confirmed within the full clinical context.

Reliable Rapid Tests Depend on a Complete Quality Chain

Rapid pregnancy tests are often known for their simplicity, but that simplicity is made possible by multiple layers of development and manufacturing control. Antibody combinations must recognize the forms of hCG relevant to the intended use. Antibody pairing, labeling chemistry, membrane materials, capillary flow, sample-handling conditions, test- and control-line design, read time, packaging systems, and instructions for use must all undergo systematic development, validation, and ongoing quality control. [5]

International biological reference materials also support hCG value assignment and test standardization. The WHO Sixth International Standard for hCG (NIBSC code 18/244), supplied by NIBSC, provides an internationally recognized reference for the calibration and comparability of hCG bioassays and immunoassays. [13] Manufacturers must still translate this reference framework into stable performance under routine production conditions and continuously manage raw materials, the production environment, processes, lots, storage, transportation, and conditions of use.

A mature rapid hCG testing system is therefore not determined by a single reagent formulation. It is the combined result of antibodies, labeling systems, membrane materials, structural components, drying and packaging systems, stability design, and manufacturing processes. Long-term, large-scale production data and market feedback can help manufacturers continuously improve consistency, manufacturability, and user experience.

The ATLAS-LINK hCG Product Family: More Than Two Decades of Experience

hCG was among the earliest diagnostic product lines established by ATLAS-LINK and remains an area of continuous development. For more than two decades, the company has expanded its pregnancy-testing portfolio for home use, professional testing, and international partnership channels, building an hCG product family represented by brands including NOVAtest® and Senso Test.

The portfolio includes products for urine, blood, and saliva applications, supported by technology platforms spanning colloidal gold, colored latex microspheres, and quantum dots. Available formats include strips, cassettes, midstream tests, and rapid-testing solutions for professional settings. ATLAS-LINK has also developed semiquantitative products that, for selected applications, provide interval-based information beyond a simple negative or positive result. Its environmentally conscious range continues to pursue resource optimization through product structure, material use, and packaging design.

According to ATLAS-LINK's internal cumulative supply records, the company has supplied several billion hCG tests, providing long-term support for large-scale testing worldwide. This manufacturing experience has deepened the company's understanding of raw-material consistency, antibody pairing, membrane selection, signal control, production environments, stability, and global transportation conditions. It has also driven the continued maturation of process controls and the quality management system.

For ATLAS-LINK, pregnancy testing is not only a long-established product line but also a long-term quality commitment: to help home users obtain preliminary information conveniently, to give professional institutions more options when rapid results are needed, and to communicate the science responsibly so that users can understand test results correctly.

Conclusion

hCG has become the central analyte in pregnancy testing because it appears early, follows measurable patterns of change during early pregnancy, and can be detected in samples including blood and urine. Urine POCT has brought pregnancy testing into homes and primary-care settings, while quantitative serum assays and rapid blood tests have extended the value of hCG to professional and specialized situations.

At the same time, hCG testing remains an aid to assessment. A positive result indicates that hCG or a related immunoreactive signal has been detected in the sample, but in certain populations and clinical contexts, pregnancy cannot be confirmed from a single positive result alone. Respecting this boundary—and considering test timing, clinical presentation, and any necessary professional confirmation—is essential to realizing the full value of hCG testing.

Building on more than two decades of R&D and manufacturing experience, ATLAS-LINK will continue to advance innovation in hCG rapid testing across sample applications, labeling technologies, result formats, and sustainable design, providing a diverse range of solutions for different testing settings.

This article is intended for scientific information only and does not replace medical diagnosis or professional clinical advice. The intended use, sample type, performance characteristics, directions for use, branding, and market availability of specific products may vary by country or region. Please refer to the locally authorized product labeling and instructions for use. References to “more than two decades” and “several billion tests” are based on ATLAS-LINK's internal business and cumulative supply records.

References

1. World Health Organization. The Selection and Use of Essential In Vitro Diagnostics: Report of the Fourth Meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022, Including the Fourth WHO Model List of Essential In Vitro Diagnostics. WHO Technical Report Series 1053. Geneva: WHO; 2023. https://www.who.int/publications/i/item/9789240081093

2. Nichols JH, Ali M, Anetor JI, et al. AACC guidance document on the use of point-of-care testing in fertility and reproduction. J Appl Lab Med. 2022;7(5):1202-1236. https://doi.org/10.1093/jalm/jfac042

3. Perrier d'Hauterive S, Close R, Gridelet V, et al. Human chorionic gonadotropin and early embryogenesis: review. Int J Mol Sci. 2022;23(3):1380. https://doi.org/10.3390/ijms23031380

4. Larrain D, Caradeux J. Beta-human chorionic gonadotropin dynamics in early gestational events: a practical and updated reappraisal. Obstet Gynecol Int. 2024;2024:8351132. https://doi.org/10.1155/2024/8351132

5. Sturgeon CM, Butler SA, Gould F, et al. Recommendations for validation testing of home pregnancy tests in Europe. Clin Chem Lab Med. 2021;59(5):823-835. https://doi.org/10.1515/cclm-2020-1523

6. Marriott L, Zinaman M, Abrams KR, Crowther MJ, Johnson S. Analysis of urinary human chorionic gonadotrophin concentrations in normal and failing pregnancies using longitudinal, Cox proportional hazards and two-stage modelling. Ann Clin Biochem. 2017;54(5):548-557. https://doi.org/10.1177/0004563216671339

7. Sundermann AC, Jasper EA, Buckley RJ, Rothman KJ, Wise LA. Home pregnancy test sensitivity by test timing and cycle length with real-world use among pregnancy planners who conceived. Fertil Steril. 2026. Online ahead of print. https://doi.org/10.1016/j.fertnstert.2026.06.022

8. Kleinschmidt S, Dugas JN, Nelson KP, Feldman JA. False negative point-of-care urine pregnancy tests in an urban academic emergency department: a retrospective cohort study. JACEP Open. 2021;2(3):e12427. https://doi.org/10.1002/emp2.12427

9. El Hage L, Hatipoglu B. Elevated hCG can be a benign finding in perimenopausal and postmenopausal women. Cleve Clin J Med. 2021;88(11):635-639. https://doi.org/10.3949/ccjm.88a.18069

10. Oyatogun O, Sandhu M, Barata-Kirby S, Tuller E, Schust DJ. A rational diagnostic approach to the 'phantom hCG' and other clinical scenarios in which a patient is thought to be pregnant but is not. Ther Adv Reprod Health. 2021;15:26334941211016412. https://doi.org/10.1177/26334941211016412

11. American College of Obstetricians and Gynecologists. Management of Positive Human Chorionic Gonadotropin Test Results in Nonpregnant Patients Without Gynecologic Malignancy. ACOG Clinical Consensus No. 11. Obstet Gynecol. 2026;147(2):e32-e38. https://doi.org/10.1097/AOG.0000000000006155

12. Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet. 2025;171(Suppl 1):78-86. https://doi.org/10.1002/ijgo.70275

13. National Institute for Biological Standards and Control. Human chorionic gonadotropin, Sixth International Standard, NIBSC code 18/244. https://nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=18%2F244